What You Should Know:
– Quest Diagnostics today announced it will acquire key assets of PathAI Diagnostics, including its state-of-the-art digital pathology laboratory in Memphis, Tennessee.
– As part of the acquisition, this facility will become Quest’s AI and digital R&D center, supporting its pathology businesses, AmeriPath, and Dermpath Diagnostics.
Digital Pathology and AI Integration
Quest will license PathAI’s AISight™ digital pathology system and AI algorithms. This will empower Quest to integrate digital pathology and AI into its existing pathology laboratories across the US. PathAI will continue to operate its independent biopharma lab, providing end-to-end clinical trial services. Quest will become a preferred provider for these services.
Unlocking the Power of Digital Pathology
Traditional cancer diagnosis relies on visual examination of tissue samples under a microscope. Digital pathology offers numerous advantages:
- Faster turnaround times: Digital slides can be shared electronically, eliminating the need for physical transportation of samples.
- Improved access to expertise: Digital slides can be reviewed by specialists remotely, regardless of location.
- Reduced workload for pathologists: AI can assist pathologists by identifying areas of concern within digital images.
“This transaction will enable Quest to dramatically ramp our capabilities in AI and digital pathology, building on our leadership in oncology and subspecialized pathology services,” said Kristie Dolan, Senior Vice President, Oncology, Quest Diagnostics. “AI and digital technologies have tremendous potential to improve cancer care, and Quest has the know-how to scale and deliver innovations that are high quality, efficient and broadly accessible. PathAI has industry-leading expertise in AI pathology innovation, and their state-of-the-art digitized laboratory in Memphis provides a platform for future growth.”
